|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Earnings: Tough Times Ahead
Author(s)Kevin Gopal
Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.
Advertisement
Articles in this issue
about 25 years ago
Research: New Horizonsabout 25 years ago
Outbreak: Anthrax Alarmabout 25 years ago
Patents: China on the Genome Mapabout 25 years ago
Privacy, Pediatrics, and Policyabout 25 years ago
Lilly's International Familyabout 25 years ago
Update: Punishment and Reprieveabout 25 years ago
Shortage: Vaccine Worriesabout 25 years ago
Gateway to Japanabout 25 years ago
SurroundedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
5